ArticleVirology journal2025
Hepatocellular jaundice in SARS-CoV-2 and EBV coinfection: a case report.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epstein-Barr virus and hepatic failure: pathogenesis, clinical manifestations, and management.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Epstein-Barr virus (EBV) are each individually associated with mild hepatic injury and, rarely, with hyperbilirubinemia. Coinfection is not well documented, and within available reports, mild hepatic injury has been demonstrated. CASE PRESENTATION: A 25-year-old man with no significant past medical history acquired coinfection and developed transaminitis, moderate hyperbilirubinemia, and hepatosplenomegaly. The degree of transaminitis was severe and out of proportion for either SARS-CoV-2 or EBV infection. The patient was admitted to the hospital for further laboratory and imaging studies to rule out other etiologies. He was managed symptomatically and without antiviral medications. The patient's transaminase levels demonstrated a pattern of recovery on day 10 with complete normalization documented at 10 months. There were no long-term sequelae.
conclusionsWhile SARS-CoV-2 and EBV are each independently associated with mild hepatic injury, this case highlights a rare presentation of severe liver injury, possibly due to synergistic viral effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.